{"id":"ampicillin","rwe":[{"pmid":"41905715","year":"2026","title":"Assessing Antibiotic Utilization Trends and Outcomes In Patients With Carbapenem-Resistant Acinetobacter Baumannii (CRAB) Infections.","finding":"","journal":"American journal of infection control","studyType":"Clinical Study"},{"pmid":"41903866","year":"2026","title":"Factors influencing the efficacy of nebulized colistimethate sodium in the treatment of severe lung infection caused by carbapenem-resistant gram-negative bacteria.","finding":"","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","studyType":"Clinical Study"},{"pmid":"41903649","year":"2026","title":"Bloody diarrhea associated with cytotoxic Aeromonas enteropelogenes harboring act and aerA genes: A case report highlighting diagnostic pitfalls.","finding":"","journal":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy","studyType":"Clinical Study"},{"pmid":"41903513","year":"2026","title":"Predictors, aetiology and outcome of early-onset neonatal bloodstream infection: a case-control study in a tertiary hospital in South Africa.","finding":"","journal":"Journal of tropical pediatrics","studyType":"Clinical Study"},{"pmid":"41902741","year":"2026","title":"Generation of equine-specific local antibiograms: reproductive tract of mares and fillies in Western Australia.","finding":"","journal":"Australian veterinary journal","studyType":"Clinical Study"}],"_fda":{"id":"0104f04f-ad00-4d3d-8107-907c6fd4ab77","set_id":"006f9a3f-b4e3-4aa5-ac65-6cc3d3e2582d","openfda":{"unii":["JFN36L5S8K","DKQ4T82YE6"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["1659592","1659598"],"spl_id":["0104f04f-ad00-4d3d-8107-907c6fd4ab77"],"brand_name":["Ampicillin and Sulbactam"],"spl_set_id":["006f9a3f-b4e3-4aa5-ac65-6cc3d3e2582d"],"package_ndc":["71288-031-91","71288-031-92","71288-032-91","71288-032-92"],"product_ndc":["71288-031","71288-032"],"generic_name":["AMPICILLIN SODIUM AND SULBACTAM SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMPICILLIN SODIUM","SULBACTAM SODIUM"],"manufacturer_name":["Meitheal Pharmaceuticals Inc."],"application_number":["ANDA065222"],"is_original_packager":[true]},"version":"2","warnings":["WARNINGS Hypersensitivity Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more apt to occur in individuals with a history of penicillin hypersensitivity and/or hypersensitivity reactions to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before therapy with a penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. If an allergic reaction occurs, ampicillin and sulbactam for injection should be discontinued and the appropriate therapy instituted. Hepatotoxicity Hepatic dysfunction, including hepatitis and cholestatic jaundice has been associated with the use of ampicillin and sulbactam for injection. Hepatic toxicity is usually reversible; however, deaths have been reported. Hepatic function should be monitored at regular intervals in patients with hepatic impairment. Severe Cutaneous Adverse Reactions Ampicillin and sulbactam for injection may cause severe skin reactions, such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), dermatitis exfoliative, erythema multiforme, and Acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash they should be monitored closely and ampicillin and sulbactam for injection discontinued if lesions progress (see CONTRAINDICATIONS and ADVERSE REACTIONS sections). Clostridium difficile - Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ampicillin and sulbactam for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C . difficile . C . difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C . difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated."],"pregnancy":["Pregnancy Reproduction studies have been performed in mice, rats, and rabbits at doses up to ten (10) times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ampicillin and sulbactam for injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed (see PRECAUTIONS Drug/Laboratory Test Interactions section)."],"overdosage":["OVERDOSAGE Neurological adverse reactions, including convulsions, may occur with the attainment of high CSF levels of beta-lactams. Ampicillin may be removed from circulation by hemodialysis. The molecular weight, degree of protein binding and pharmacokinetics profile of sulbactam suggest that this compound may also be removed by hemodialysis."],"description":["DESCRIPTION Ampicillin and Sulbactam for Injection, USP is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C 16 H 18 N 3 NaO 4 S. The structural formula is: Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C 8 H 10 NNaO 5 S with a molecular weight of 255.22. The structural formula is: Ampicillin and Sulbactam for Injection, USP, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. Ampicillin and Sulbactam for Injection, USP dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8.0 and 10.0. Dilute solutions (up to 30 mg ampicillin and 15 mg sulbactam per mL) are essentially colorless to pale yellow. The pH of dilute solutions remains the same. 1.5 g of Ampicillin and Sulbactam for Injection, USP (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) parenteral contains approximately 115 mg (5 mEq) of sodium. 3 g of Ampicillin and Sulbactam for Injection, USP (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) parenteral contains approximately 230 mg (10 mEq) of sodium. Structural Formula Structural Formula"],"precautions":["PRECAUTIONS General A high percentage of patients with mononucleosis who receive ampicillin develop a skin rash. Thus, ampicillin class antibacterials should not be administered to patients with mononucleosis. In patients treated with ampicillin and sulbactam for injection the possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving Pseudomonas or Candida ), the drug should be discontinued and/or appropriate therapy instituted. Prescribing ampicillin and sulbactam for injection in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Information for Patients Patients should be counseled that antibacterial drugs including ampicillin and sulbactam for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When ampicillin and sulbactam for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ampicillin and sulbactam for injection or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible. Drug Interactions Probenecid decreases the renal tubular secretion of ampicillin and sulbactam. Concurrent use of probenecid with ampicillin and sulbactam for injection may result in increased and prolonged blood levels of ampicillin and sulbactam. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with ampicillin and sulbactam for injection and allopurinol administered concurrently. Ampicillin and sulbactam for injection and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of ampicillin and sulbactam for injection. Drug/Laboratory Test Interactions Administration of ampicillin and sulbactam for injection will result in high urine concentration of ampicillin. High urine concentrations of ampicillin may result in false positive reactions when testing for the presence of glucose in urine using Clinitest™, Benedict's Solution or Fehling's Solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix™ or Testape™) be used. Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with ampicillin and sulbactam for injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential. Pregnancy Reproduction studies have been performed in mice, rats, and rabbits at doses up to ten (10) times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ampicillin and sulbactam for injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed (see PRECAUTIONS Drug/Laboratory Test Interactions section). Labor and Delivery Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of ampicillin and sulbactam for injection in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary. Nursing Mothers Low concentrations of ampicillin and sulbactam are excreted in the milk; therefore, caution should be exercised when ampicillin and sulbactam for injection is administered to a nursing woman. Pediatric Use The safety and effectiveness of ampicillin and sulbactam for injection have been established for pediatric patients one year of age and older for skin and skin structure infections as approved in adults. Use of ampicillin and sulbactam for injection in pediatric patients is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetic studies, a controlled clinical trial conducted in pediatric patients and post-marketing adverse events surveillance (see CLINICAL PHARMACOLOGY , INDICATIONS AND USAGE , ADVERSE REACTIONS , DOSAGE AND ADMINISTRATION , and CLINICAL STUDIES sections). The safety and effectiveness of ampicillin and sulbactam for injection have not been established for pediatric patients for intra-abdominal infections."],"how_supplied":["HOW SUPPLIED Ampicillin and Sulbactam for Injection, USP (ampicillin sodium/sulbactam sodium) is a sterile white to off-white dry powder and is supplied in 20 mL glass vials as follows: NDC Ampicillin and Sulbactam for Injection, USP Package Factor 71288- 031 -92 1.5 gram equivalent 10 vials per tray (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) in a Single-Dose Vial 71288- 032 -92 3 gram equivalent 10 vials per tray (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) in a Single-Dose Vial Ampicillin and Sulbactam for Injection, USP powder should be stored at or below 86ºF (30ºC), prior to reconstitution. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex. For medical information about Ampicillin and Sulbactam for Injection, USP, please visit www.meithealpharma.com or call 1-844-824-8426. To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. This product’s labeling may have been updated. For the most recent prescribing information, please visit www.meithealpharma.com. Brands listed are the trademarks of their respective owners. Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) ©2025 Meitheal Pharmaceuticals Inc. Mfd. by Istituto Biochimico Italiano Aprilia, Italy 04011 Novaplus is a registered trademark of Vizient, Inc. Revised: April 2025 novaplus+ TM 860813/01"],"microbiology":["MICROBIOLOGY Ampicillin is similar to benzyl penicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopeptide biosynthesis. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. (Ampicillin is, however, degraded by beta-lactamases and therefore the spectrum of activity does not normally include organisms which produce these enzymes). A wide range of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins have been shown in biochemical studies with cell free bacterial systems to be irreversibly inhibited by sulbactam. Although sulbactam alone possesses little useful antibacterial activity except against the Neisseriaceae , whole organism studies have shown that sulbactam restores ampicillin activity against beta-lactamase producing strains. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta-lactamases most frequently responsible for transferred drug resistance. Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible strains. The presence of sulbactam in the ampicillin and sulbactam for injection formulation effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibacterials. Thus, ampicillin and sulbactam for injection possesses the properties of a broad-spectrum antibacterial and a beta-lactamase inhibitor. While in vitro studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the INDICATIONS and USAGE section has not been documented. Gram-Positive Bacteria Staphylococcus aureus (beta-lactamase and non-beta-lactamase producing), Staphylococcus epidermidis (beta-lactamase and non-beta-lactamase producing), Staphylococcus saprophyticus (beta-lactamase and non-beta-lactamase producing), Streptococcus faecalis † (Enterococcus), Streptococcus pneumoniae † (formerly D . pneumoniae ), Streptococcus pyogenes † , Streptococcus viridans † . Gram-Negative Bacteria Hemophilus influenzae (beta-lactamase and non-beta-lactamase producing), Moraxella ( Branhamella ) catarrhalis (beta-lactamase and non-beta-lactamase producing), Escherichia coli (beta-lactamase and non-beta-lactamase producing), Klebsiella species (all known strains are beta-lactamase producing), Proteus mirabilis (beta-lactamase and non-beta-lactamase producing), Proteus vulgaris , Providencia rettgeri , Providencia stuartii , Morganella morganii , and Neisseria gonorrhoeae (beta-lactamase and non-beta-lactamase producing). Anaerobes Clostridium species, † Peptococcus species, † Peptostreptococcus species, Bacteroides species, including B. fragilis . † These are not beta-lactamase producing strains and, therefore, are susceptible to ampicillin alone. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"pediatric_use":["Pediatric Use The safety and effectiveness of ampicillin and sulbactam for injection have been established for pediatric patients one year of age and older for skin and skin structure infections as approved in adults. Use of ampicillin and sulbactam for injection in pediatric patients is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetic studies, a controlled clinical trial conducted in pediatric patients and post-marketing adverse events surveillance (see CLINICAL PHARMACOLOGY , INDICATIONS AND USAGE , ADVERSE REACTIONS , DOSAGE AND ADMINISTRATION , and CLINICAL STUDIES sections). The safety and effectiveness of ampicillin and sulbactam for injection have not been established for pediatric patients for intra-abdominal infections."],"effective_time":"20250722","nursing_mothers":["Nursing Mothers Low concentrations of ampicillin and sulbactam are excreted in the milk; therefore, caution should be exercised when ampicillin and sulbactam for injection is administered to a nursing woman."],"clinical_studies":["CLINICAL STUDIES Skin and Skin Structure Infections in Pediatric Patients Data from a controlled clinical trial conducted in pediatric patients provided evidence supporting the safety and efficacy of ampicillin and sulbactam for injection for the treatment of skin and skin structure infections. Of 99 pediatric patients evaluable for clinical efficacy, 60 patients received a regimen containing intravenous ampicillin and sulbactam for injection, and 39 patients received a regimen containing intravenous cefuroxime. This trial demonstrated similar outcomes (assessed at an appropriate interval after discontinuation of all antimicrobial therapy) for ampicillin and sulbactam for injection- and cefuroxime-treated patients: TABLE 2 Therapeutic Regimen Clinical Success Clinical Failure Ampicillin and Sulbactam for Injection, USP 51/60 (85%) 9/60 (15%) Cefuroxime 34/39 (87%) 5/39 (13%) Most patients received a course of oral antimicrobials following initial treatment with intravenous administration of parenteral antimicrobials. The study protocol required that the following three criteria be met prior to transition from intravenous to oral antimicrobial therapy: (1) receipt of a minimum of 72 hours of intravenous therapy; (2) no documented fever for prior 24 hours; and (3) improvement or resolution of the signs and symptoms of infection. The choice of oral antimicrobial agent used in this trial was determined by susceptibility testing of the original pathogen, if isolated, to oral agents available. The course of oral antimicrobial therapy should not routinely exceed 14 days."],"adverse_reactions":["ADVERSE REACTIONS Adult Patients Ampicillin and sulbactam for injection is generally well tolerated. The following adverse reactions have been reported in clinical trials. Local Adverse Reactions Pain at IM injection site – 16% Pain at IV injection site – 3% Thrombophlebitis – 3% Phlebitis – 1.2% Systemic Adverse Reactions The most frequently reported adverse reactions were diarrhea in 3% of the patients and rash in less than 2% of the patients. Additional systemic reactions reported in less than 1% of the patients were: itching, nausea, vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension, glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat, substernal pain, epistaxis and mucosal bleeding. Pediatric Patients Available safety data for pediatric patients treated with ampicillin and sulbactam for injection demonstrate a similar adverse events profile to those observed in adult patients. Additionally, atypical lymphocytosis has been observed in one pediatric patient receiving ampicillin and sulbactam for injection. Adverse Laboratory Changes Adverse laboratory changes without regard to drug relationship that were reported during clinical trials were: Hepatic : Increased AST (SGOT), ALT (SGPT), alkaline phosphatase, and LDH. Hematologic : Decreased hemoglobin, hematocrit, RBC, WBC, neutrophils, lymphocytes, platelets and increased lymphocytes, monocytes, basophils, eosinophils, and platelets. Blood Chemistry : Decreased serum albumin and total proteins. Renal : Increased BUN and creatinine. Urinalysis : Presence of RBC's and hyaline casts in urine. Postmarketing Experience In addition to adverse reactions reported from clinical trials, the following have been identified during post-marketing use of ampicillin sodium/sulbactam sodium or other products containing ampicillin. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency, or potential causal connection to ampicillin sodium/sulbactam sodium. Blood and Lymphatic System Disorders Hemolytic anemia, thrombocytopenic purpura, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Some individuals have developed positive direct Coombs Tests during treatment with ampicillin and sulbactam for injection, as with other beta-lactam antibacterials. Gastrointestinal Disorders Abdominal pain, cholestatic hepatitis, cholestasis, hyperbilirubinemia, jaundice, abnormal hepatic function, melena, gastritis, stomatitis, dyspepsia, black “hairy” tongue, and Clostridium difficile associated diarrhea (see CONTRAINDICATIONS and WARNINGS sections). General Disorders and Administration Site Conditions Injection site reaction Immune System Disorders Serious and fatal hypersensitivity (anaphylactic) reactions (see WARNINGS section), Acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction. Nervous System Disorders Convulsion and dizziness Renal and Urinary Disorders Tubulointerstitial nephritis Respiratory, Thoracic and Mediastinal Disorders Dyspnea Skin and Subcutaneous Tissue Disorders Toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, Acute generalized exanthematous pustulosis (AGEP), erythema multiforme, exfoliative dermatitis, urticaria (see CONTRAINDICATIONS and WARNINGS sections), and linear IgA bullous dermatosis."],"contraindications":["CONTRAINDICATIONS The use of ampicillin and sulbactam for injection is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). Ampicillin and sulbactam for injection is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with ampicillin and sulbactam for injection."],"drug_interactions":["Drug Interactions Probenecid decreases the renal tubular secretion of ampicillin and sulbactam. Concurrent use of probenecid with ampicillin and sulbactam for injection may result in increased and prolonged blood levels of ampicillin and sulbactam. The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with ampicillin and sulbactam for injection and allopurinol administered concurrently. Ampicillin and sulbactam for injection and aminoglycosides should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the ampicillin component of ampicillin and sulbactam for injection."],"how_supplied_table":["
NDCAmpicillin and Sulbactam for Injection, USPPackage Factor
71288-031-921.5 gram equivalent10 vials per tray
(1 g ampicillin as the sodium salt plus 0.5 g
sulbactam as the sodium salt) in a Single-Dose Vial
","
71288-032-923 gram equivalent10 vials per tray
(2 g ampicillin as the sodium salt plus 1 g
sulbactam as the sodium salt) in a Single-Dose Vial
"],"labor_and_delivery":["Labor and Delivery Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of ampicillin and sulbactam for injection in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary."],"general_precautions":["General A high percentage of patients with mononucleosis who receive ampicillin develop a skin rash. Thus, ampicillin class antibacterials should not be administered to patients with mononucleosis. In patients treated with ampicillin and sulbactam for injection the possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving Pseudomonas or Candida ), the drug should be discontinued and/or appropriate therapy instituted. Prescribing ampicillin and sulbactam for injection in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"storage_and_handling":["Ampicillin and Sulbactam for Injection, USP powder should be stored at or below 86ºF (30ºC), prior to reconstitution. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex. For medical information about Ampicillin and Sulbactam for Injection, USP, please visit www.meithealpharma.com or call 1-844-824-8426. To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. This product’s labeling may have been updated. For the most recent prescribing information, please visit www.meithealpharma.com. Brands listed are the trademarks of their respective owners. Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) ©2025 Meitheal Pharmaceuticals Inc. Mfd. by Istituto Biochimico Italiano Aprilia, Italy 04011 Novaplus is a registered trademark of Vizient, Inc. Revised: April 2025 novaplus+ TM 860813/01"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY General Immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam for injection, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of ampicillin alone. Peak ampicillin serum levels ranging from 109 to 150 mcg/mL are attained after administration of 2000 mg of ampicillin plus 1000 mg sulbactam and 40 to 71 mcg/mL after administration of 1000 mg ampicillin plus 500 mg sulbactam. The corresponding mean peak serum levels for sulbactam range from 48 to 88 mcg/mL and 21 to 40 mcg/mL, respectively. After an intramuscular injection of 1000 mg ampicillin plus 500 mg sulbactam, peak ampicillin serum levels ranging from 8 to 37 mcg/mL and peak sulbactam serum levels ranging from 6 to 24 mcg/mL are attained. The mean serum half-life of both drugs is approximately 1 hour in healthy volunteers. Approximately 75 to 85% of both ampicillin and sulbactam are excreted unchanged in the urine during the first 8 hours after administration of ampicillin and sulbactam for injection to individuals with normal renal function. Somewhat higher and more prolonged serum levels of ampicillin and sulbactam can be achieved with the concurrent administration of probenecid. In patients with impaired renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of ampicillin and sulbactam for injection in such patients should be administered less frequently in accordance with the usual practice for ampicillin (see DOSAGE and ADMINISTRATION section). Ampicillin has been found to be approximately 28% reversibly bound to human serum protein and sulbactam approximately 38% reversibly bound. The following average levels of ampicillin and sulbactam were measured in the tissues and fluids listed: TABLE 1 Concentration of Ampicillin and Sulbactam for Injection in Various Body Tissues and Fluids Fluid or Tissue Dose (grams) Ampicillin/Sulbactam Concentration (mcg/mL or mcg/g) Ampicillin/Sulbactam Peritoneal Fluid 0.5/0.5 IV 7/14 Blister Fluid (Cantharides) 0.5/0.5 IV 8/20 Tissue Fluid 1/0.5 IV 8/4 Intestinal Mucosa 0.5/0.5 IV 11/18 Appendix 2/1 IV 3/40 Penetration of both ampicillin and sulbactam into cerebrospinal fluid in the presence of inflamed meninges has been demonstrated after IV administration of ampicillin and sulbactam for injection. The pharmacokinetics of ampicillin and sulbactam in pediatric patients receiving ampicillin and sulbactam for injection are similar to those observed in adults. Immediately after a 15-minute infusion of 50 to 75 mg ampicillin and sulbactam for injection /kg body weight, peak serum and plasma concentrations of 82 to 446 mcg ampicillin/mL and 44 to 203 mcg sulbactam/mL were obtained. Mean half-life values were approximately 1 hour."],"indications_and_usage":["INDICATIONS AND USAGE Ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus , Escherichia coli ,* Klebsiella spp.* (including K. pneumoniae *), Proteus mirabilis ,* Bacteroides fragilis ,* Enterobacter spp.,* and Acinetobacter calcoaceticus .* NOTE: For information on use in pediatric patients (see PRECAUTIONS-Pediatric Use and CLINICAL STUDIES sections). Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli , Klebsiella spp. (including K. pneumoniae *), Bacteroides spp. (including B. fragilis ), and Enterobacter spp.* Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli ,* and Bacteroides spp.* (including B. fragilis *). * Efficacy for this organism in this organ system was studied in fewer than 10 infections. While ampicillin and sulbactam for injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with ampicillin and sulbactam for injection due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to ampicillin and sulbactam for injection should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to ampicillin and sulbactam for injection. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of ampicillin and sulbactam for injection and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"clinical_studies_table":["
TABLE 2
Therapeutic RegimenClinical SuccessClinical Failure
Ampicillin and Sulbactam for Injection, USP51/60 (85%)9/60 (15%)
Cefuroxime34/39 (87%)5/39 (13%)
"],"information_for_patients":["Information for Patients Patients should be counseled that antibacterial drugs including ampicillin and sulbactam for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When ampicillin and sulbactam for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ampicillin and sulbactam for injection or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible."],"spl_unclassified_section":["Rx only novaplus+ TM To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin and Sulbactam for Injection, USP and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.","COMPATIBILITY, RECONSTITUTION AND STABILITY Ampicillin and sulbactam for injection sterile powder is to be stored at or below 30°C (86°F) prior to reconstitution. When concomitant therapy with aminoglycosides is indicated, ampicillin and sulbactam for injection and aminoglycosides should be reconstituted and administered separately, due to the in vitro inactivation of aminoglycosides by any of the aminopenicillins.","DIRECTIONS FOR USE General Dissolution Procedures Ampicillin and sulbactam for injection sterile powder for intravenous and intramuscular use may be reconstituted with any of the compatible diluents described in this insert. Solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization. Preparation for Intravenous Use 1.5 g and 3.0 g Bottles: ampicillin and sulbactam for injection sterile powder in piggyback units may be reconstituted directly to the desired concentrations using any of the following parenteral diluents. Reconstitution of ampicillin and sulbactam for injection, at the specified concentrations, with these diluents provide stable solutions for the time periods indicated in the following table: (After the indicated time periods, any unused portions of solutions should be discarded). TABLE 4 Diluent Maximum Concentration (mg per mL) Ampicillin and Sulbactam for Injection Use Periods Sterile Water for Injection 45 (30/15) 8 hrs at 25°C 45 (30/15) 48 hrs at 4°C 30 (20/10) 72 hrs at 4°C 0.9% Sodium Chloride Injection 45 (30/15) 8 hrs at 25°C 45 (30/15) 48 hrs at 4°C 30 (20/10) 72 hrs at 4°C 5% Dextrose Injection 30 (20/10) 2 hrs at 25°C 30 (20/10) 4 hrs at 4°C 3 (2/1) 4 hrs at 25°C Lactated Ringer's Injection 45 (30/15) 8 hrs at 25°C 45 (30/15) 24 hrs at 4°C M/6 Sodium Lactate Injection 45 (30/15) 8 hrs at 25°C 45 (30/15) 8 hrs at 4°C 5% Dextrose in 0.45% Saline 3 (2/1) 4 hrs at 25°C 15 (10/5) 4 hrs at 4°C 10% Invert Sugar 3 (2/1) 4 hrs at 25°C 30 (20/10) 3 hrs at 4°C If piggyback bottles are unavailable, standard vials of ampicillin and sulbactam for injection sterile powder may be used. Initially, the vials may be reconstituted with Sterile Water for Injection to yield solutions containing 375 mg ampicillin and sulbactam for injection per mL (250 mg ampicillin/125 mg sulbactam per mL). An appropriate volume should then be immediately diluted with a suitable parenteral diluent to yield solutions containing 3 to 45 mg ampicillin and sulbactam for injection per mL (2 to 30 mg ampicillin/1 to 15 mg sulbactam per mL). In 0.9% Sodium Chloride Injection, USP The final diluted solution of ampicillin and sulbactam for injection should be completely administered within 8 hours in order to assure proper potency.","Preparation for Intramuscular Injection 1.5 g and 3.0 g Standard Vials Vials for intramuscular use may be reconstituted with Sterile Water for Injection USP, 0.5% Lidocaine Hydrochloride Injection USP or 2% Lidocaine Hydrochloride Injection USP. Consult the following table for recommended volumes to be added to obtain solutions containing 375 mg ampicillin and sulbactam for injection per mL (250 mg ampicillin/125 mg sulbactam per mL). Note: Use only freshly prepared solutions and administer within one hour after preparation. TABLE 6 *There is sufficient excess present to allow withdrawal and administration of the stated volumes. Ampicillin and Sulbactam for Injection Vial Size Volume of Diluent to be Added Withdrawal Volume* 1.5 g 3.2 mL 4.0 mL 3.0 g 6.4 mL 8.0 mL Animal Pharmacology While reversible glycogenosis was observed in laboratory animals, this phenomenon was dose-and time-dependent and is not expected to develop at the therapeutic doses and corresponding plasma levels attained during the relatively short periods of combined ampicillin/sulbactam therapy in man."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Ampicillin and sulbactam for injection may be administered by either the IV or the IM routes. For IV administration, the dose can be given by slow intravenous injection over at least 10-15 minutes or can also be delivered in greater dilutions with 50-100 mL of a compatible diluent as an intravenous infusion over 15-30 minutes. Ampicillin and sulbactam for injection may be administered by deep intramuscular injection (see DIRECTIONS FOR USE-Preparation for Intramuscular Injection section). The recommended adult dosage of ampicillin and sulbactam for injection is 1.5 g (1 g ampicillin as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g ampicillin as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours. This 1.5 to 3 g range represents the total of ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection, and corresponds to a range of 1 g ampicillin/0.5 g sulbactam to 2 g ampicillin/1 g sulbactam. The total dose of sulbactam should not exceed 4 grams per day. Pediatric Patients 1 Year of Age or Older The recommended daily dose of ampicillin and sulbactam for injection in pediatric patients is 300 mg per kg of body weight administered via intravenous infusion in equally divided doses every 6 hours. This 300 mg/kg/day dosage represents the total ampicillin content plus the sulbactam content of ampicillin and sulbactam for injection, and corresponds to 200 mg ampicillin/100 mg sulbactam per kg per day. The safety and efficacy of ampicillin and sulbactam for injection administered via intramuscular injection in pediatric patients have not been established. Pediatric patients weighing 40 kg or more should be dosed according to adult recommendations, and the total dose of sulbactam should not exceed 4 grams per day. The course of intravenous therapy should not routinely exceed 14 days. In clinical trials, most children received a course of oral antimicrobials following initial treatment with intravenous ampicillin and sulbactam for injection (see CLINICAL STUDIES section). Impaired Renal Function In patients with impairment of renal function the elimination kinetics of ampicillin and sulbactam are similarly affected, hence the ratio of one to the other will remain constant whatever the renal function. The dose of ampicillin and sulbactam for injection in such patients should be administered less frequently in accordance with the usual practice for ampicillin and according to the following recommendations: TABLE 3 Ampicillin and Sulbactam for Injection Dosage Guide for Patients with Renal Impairment Creatinine Clearance (mL/min/1.73m 2 ) Ampicillin/Sulbactam Half-Life (Hours) Recommended Ampicillin and Sulbactam for Injection Dosage ≥30 1 1.5-3 g q 6h-q 8h 15-29 5 1.5-3 g q 12h 5-14 9 1.5-3 g q 24h When only serum creatinine is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function. Males weight (kg) x (140 - age) 72 x serum creatinine Females 0.85 x above value"],"spl_product_data_elements":["Ampicillin and Sulbactam Ampicillin sodium and Sulbactam sodium ampicillin sodium ampicillin sulbactam sodium sulbactam Ampicillin and Sulbactam Ampicillin sodium and Sulbactam sodium ampicillin sodium ampicillin sulbactam sodium sulbactam"],"clinical_pharmacology_table":["
TABLE 1
Concentration of Ampicillin and Sulbactam for Injection in Various Body Tissues and Fluids
Fluid or TissueDose (grams) Ampicillin/SulbactamConcentration (mcg/mL or mcg/g) Ampicillin/Sulbactam
Peritoneal Fluid0.5/0.5 IV7/14
Blister Fluid (Cantharides)0.5/0.5 IV8/20
Tissue Fluid1/0.5 IV8/4
Intestinal Mucosa0.5/0.5 IV11/18
Appendix2/1 IV3/40
"],"spl_unclassified_section_table":["
TABLE 4
DiluentMaximum Concentration (mg per mL) Ampicillin and Sulbactam for Injection Use Periods
Sterile Water for Injection45 (30/15)8 hrs at 25°C
45 (30/15)48 hrs at 4°C
30 (20/10)72 hrs at 4°C
0.9% Sodium Chloride Injection45 (30/15)8 hrs at 25°C
45 (30/15)48 hrs at 4°C
30 (20/10)72 hrs at 4°C
5% Dextrose Injection30 (20/10)2 hrs at 25°C
30 (20/10)4 hrs at 4°C
3 (2/1)4 hrs at 25°C
Lactated Ringer's Injection45 (30/15)8 hrs at 25°C
45 (30/15)24 hrs at 4°C
M/6 Sodium Lactate Injection45 (30/15)8 hrs at 25°C
45 (30/15)8 hrs at 4°C
5% Dextrose in 0.45% Saline3 (2/1)4 hrs at 25°C
15 (10/5)4 hrs at 4°C
10% Invert Sugar3 (2/1)4 hrs at 25°C
30 (20/10)3 hrs at 4°C
","
TABLE 6
*There is sufficient excess present to allow withdrawal and administration of the stated volumes.
Ampicillin and Sulbactam for Injection Vial Size Volume of Diluent to be Added Withdrawal Volume*
1.5 g3.2 mL4.0 mL
3.0 g6.4 mL8.0 mL
"],"dosage_and_administration_table":["
TABLE 3
Ampicillin and Sulbactam for Injection Dosage Guide for Patients with Renal Impairment
Creatinine Clearance (mL/min/1.73m2)Ampicillin/Sulbactam Half-Life (Hours)Recommended Ampicillin and Sulbactam for Injection Dosage
≥3011.5-3 g q 6h-q 8h
15-2951.5-3 g q 12h
5-1491.5-3 g q 24h
","
Malesweight (kg) x (140 - age)
72 x serum creatinine
Females0.85 x above value
"],"package_label_principal_display_panel":["Principal Display Panel – Ampicillin and Sulbactam for Injection, USP 1.5 gram Vial Label NDC 71288-031-91 Rx ONLY Ampicillin and Sulbactam for Injection, USP For Intramuscular or Intravenous Use 1.5 grams* per vial Single-Dose Vial Principal Display Panel – Ampicillin and Sulbactam for Injection, USP 1.5 gram Vial Label","Principal Display Panel - Ampicillin and Sulbactam for Injection, USP 1.5 gram Carton NDC 71288-031-92 Rx ONLY Ampicillin and Sulbactam for Injection, USP For Intramuscular or Intravenous Use 1.5 grams* per vial 10 Vials Sterile 10 x 1.5 Grams Single-Dose Vials Principal Display Panel - Ampicillin and Sulbactam for Injection, USP 1.5 gram Carton","Principal Display Panel – Ampicillin and Sulbactam for Injection, USP 3 gram Vial Label NDC 71288-032-91 Rx ONLY Ampicillin and Sulbactam for Injection, USP For Intramuscular or Intravenous Use 3 grams* per vial Single-Dose Vial Principal Display Panel – Ampicillin and Sulbactam for Injection, USP 3 gram Vial Label","Principal Display Panel – Ampicillin and Sulbactam for Injection, USP 3 gram Carton NDC 71288-032-92 Rx ONLY Ampicillin and Sulbactam for Injection, USP For Intramuscular or Intravenous Use 3 grams* per vial 10 Vials Sterile 10 x 3 Grams Single-Dose Vials Principal Display Panel – Ampicillin and Sulbactam for Injection, USP 3 gram Carton"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions Administration of ampicillin and sulbactam for injection will result in high urine concentration of ampicillin. High urine concentrations of ampicillin may result in false positive reactions when testing for the presence of glucose in urine using Clinitest™, Benedict's Solution or Fehling's Solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix™ or Testape™) be used. Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with ampicillin and sulbactam for injection."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential."]},"tags":[{"label":"Penicillin-class Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Transient receptor potential cation channel subfamily M member 4","category":"target"},{"label":"TRPM4","category":"gene"},{"label":"TEK","category":"gene"},{"label":"J01CA01","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acute bacterial epiglottitis","category":"indication"},{"label":"Acute bacterial sinusitis","category":"indication"},{"label":"Acute epiglottitis","category":"indication"},{"label":"Acute exacerbation of chronic bronchitis","category":"indication"},{"label":"Acute gonococcal cervicitis","category":"indication"},{"label":"Acute gonococcal endometritis","category":"indication"},{"label":"Apothecon","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"957 reports"},{"date":"","signal":"FOETAL EXPOSURE DURING PREGNANCY","source":"FDA FAERS","actionTaken":"670 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"656 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"559 reports"},{"date":"","signal":"MATERNAL EXPOSURE DURING PREGNANCY","source":"FDA FAERS","actionTaken":"546 reports"},{"date":"","signal":"PREMATURE BABY","source":"FDA FAERS","actionTaken":"527 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"472 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"423 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"368 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"368 reports"}],"drugInteractions":[{"url":"/drug/desogestrel","drug":"desogestrel","action":"Monitor closely","effect":"May interact with Desogestrel","source":"DrugCentral","drugSlug":"desogestrel"},{"url":"/drug/ethinylestradiol","drug":"ethinylestradiol","action":"Monitor closely","effect":"May interact with Ethinyl Estradiol","source":"DrugCentral","drugSlug":"ethinylestradiol"},{"url":"/drug/gentamicin","drug":"gentamicin","action":"Monitor closely","effect":"May interact with Gentamicin","source":"DrugCentral","drugSlug":"gentamicin"},{"url":"/drug/levonorgestrel","drug":"levonorgestrel","action":"Monitor closely","effect":"May interact with Levonorgestrel","source":"DrugCentral","drugSlug":"levonorgestrel"},{"url":"/drug/mestranol","drug":"mestranol","action":"Monitor closely","effect":"May interact with Mestranol","source":"DrugCentral","drugSlug":"mestranol"},{"url":"/drug/netilmicin","drug":"netilmicin","action":"Monitor closely","effect":"May interact with Netilmicin","source":"DrugCentral","drugSlug":"netilmicin"},{"url":"/drug/norelgestromin","drug":"norelgestromin","action":"Monitor closely","effect":"May interact with Norelgestromin","source":"DrugCentral","drugSlug":"norelgestromin"},{"url":"/drug/norethisterone","drug":"norethisterone","action":"Monitor closely","effect":"May interact with Norethindrone","source":"DrugCentral","drugSlug":"norethisterone"},{"url":"/drug/norethynodrel","drug":"norethynodrel","action":"Monitor closely","effect":"May interact with Norethynodrel","source":"DrugCentral","drugSlug":"norethynodrel"},{"url":"/drug/norgestimate","drug":"norgestimate","action":"Monitor closely","effect":"May interact with Norgestimate","source":"DrugCentral","drugSlug":"norgestimate"},{"url":"/drug/tobramycin","drug":"tobramycin","action":"Monitor closely","effect":"May interact with Tobramycin","source":"DrugCentral","drugSlug":"tobramycin"}],"commonSideEffects":[{"effect":"Anaphylaxis","drugRate":"reported","severity":"serious"},{"effect":"Anaphylactoid reactions","drugRate":"reported","severity":"serious"},{"effect":"Eosinophilia","drugRate":"reported","severity":"mild"},{"effect":"Erythema multiforme","drugRate":"reported","severity":"mild"},{"effect":"Exfoliative dermatitis","drugRate":"reported","severity":"serious"},{"effect":"Glossitis","drugRate":"reported","severity":"mild"},{"effect":"Leukopenia","drugRate":"reported","severity":"mild"},{"effect":"Laryngeal stridor","drugRate":"reported","severity":"mild"},{"effect":"Nausea","drugRate":"reported","severity":"mild"},{"effect":"Pseudomembranous colitis","drugRate":"reported","severity":"serious"},{"effect":"Pruritus","drugRate":"reported","severity":"mild"},{"effect":"Serum sicknesslike reactions","drugRate":"reported","severity":"mild"},{"effect":"Skin rash","drugRate":"reported","severity":"mild"},{"effect":"Stomatitis","drugRate":"reported","severity":"mild"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"mild"},{"effect":"Thrombocytopenic purpura","drugRate":"reported","severity":"mild"},{"effect":"Urticaria","drugRate":"reported","severity":"mild"},{"effect":"Vomiting","drugRate":"reported","severity":"mild"},{"effect":"Diarrhea","drugRate":"reported","severity":"mild"},{"effect":"Enterocolitis","drugRate":"reported","severity":"serious"},{"effect":"Erythematous, mildly pruritic, maculopapular skin rash","drugRate":"reported","severity":"mild"},{"effect":"Anemia","drugRate":"reported","severity":"mild"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"serious"},{"effect":"High fever","drugRate":"reported","severity":"serious"},{"effect":"Liver: Moderate elevation in serum glutamic oxaloacetic transaminase (SGOT)","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Anemia due to enzyme deficiency","Disease of blood AND/OR blood-forming organ","Impaired renal function disorder","Infectious mononucleosis","Kidney disease","Peptic ulcer","Pseudomembranous enterocolitis","Uric Acid Nephropathy Gout","Uric acid renal calculus"],"specialPopulations":{"Pregnancy":"Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Paediatric use":"The safety and effectiveness of ampicillin and sulbactam for injection have been established for pediatric patients one year of age and older for skin and skin structure infections as approved in adults."}},"trials":[],"aliases":[],"company":"Bristol-Myers Squibb","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.4894/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$179","description":"AMPICILLIN 500 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMPICILLIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:38:49.771831+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:38:56.057773+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:38:48.886338+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPICILLIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:38:56.406228+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:38:46.258004+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:38:46.258030+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:38:58.029585+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:38:57.580717+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200758/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:38:57.240137+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA065222","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:38:46.258034+00:00"}},"allNames":"unasyn","offLabel":[],"synonyms":["ampicillin hydrate","ampicillin","ampicillin sodium","ampicillin trihydrate","ampicillin anhydrous"],"timeline":[{"date":"1965-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from WYETH AYERST to Apothecon"},{"date":"1965-12-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Wyeth Ayerst)"}],"aiSummary":"Unasyn (Ampicillin) is a penicillin-class antibacterial drug originally developed by Wyeth Ayerst and currently owned by Apothecon. It targets the transient receptor potential cation channel subfamily M member 4 and is used to treat various bacterial infections, including acute epiglottitis, sinusitis, and gonococcal infections. Unasyn is a small molecule with a half-life of 1.4 hours and bioavailability of 62%. It is off-patent and has multiple generic manufacturers. Key safety considerations include its potential to cause allergic reactions and interact with other medications.","brandName":"Unasyn","ecosystem":[{"indication":"Acute bacterial epiglottitis","otherDrugs":[],"globalPrevalence":null},{"indication":"Acute bacterial sinusitis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefdinir","slug":"cefdinir","company":""}],"globalPrevalence":null},{"indication":"Acute epiglottitis","otherDrugs":[],"globalPrevalence":null},{"indication":"Acute exacerbation of chronic bronchitis","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefditoren pivoxil","slug":"cefditoren-pivoxil","company":"Vansen Pharma"},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Acute gonococcal cervicitis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Acute gonococcal endometritis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"cefotetan","slug":"cefotetan","company":""},{"name":"cefoxitin","slug":"cefoxitin","company":""},{"name":"ceftizoxime","slug":"ceftizoxime","company":""}],"globalPrevalence":null},{"indication":"Acute gonococcal urethritis","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Acute otitis media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":709000000}],"mechanism":{"target":"Transient receptor potential cation channel subfamily M member 4","novelty":"Follow-on","targets":[{"gene":"TRPM4","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily M member 4","protein":"Transient receptor potential cation channel subfamily M member 4"},{"gene":"TEK","source":"DrugCentral","target":"Angiopoietin-1 receptor","protein":"Angiopoietin-1 receptor"}],"modality":"Small Molecule","drugClass":"Penicillin-class Antibacterial","explanation":"","oneSentence":"","technicalDetail":"Unasyn exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the transpeptidation reaction that is essential for bacterial cell wall synthesis."},"commercial":{"launchDate":"1965","_launchSource":"DrugCentral (FDA 1965-12-17, WYETH AYERST)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/198","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMPICILLIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPICILLIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:47:00.026512","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:00.779187+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"carbenicillin","drugSlug":"carbenicillin","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"amoxicillin","drugSlug":"amoxicillin","fdaApproval":"1974-12-09","patentExpiry":"May 7, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"carindacillin","drugSlug":"carindacillin","fdaApproval":"1972-10-26","relationship":"same-class"},{"drugName":"bacampicillin","drugSlug":"bacampicillin","fdaApproval":"1980-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"azlocillin","drugSlug":"azlocillin","fdaApproval":"1982-09-03","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mezlocillin","drugSlug":"mezlocillin","fdaApproval":"1981-09-21","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mecillinam","drugSlug":"mecillinam","fdaApproval":"","relationship":"same-class"},{"drugName":"piperacillin","drugSlug":"piperacillin","fdaApproval":"1981-12-29","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ticarcillin","drugSlug":"ticarcillin","fdaApproval":"1976-11-09","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hetacillin","drugSlug":"hetacillin","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"ampicillin","indications":{"approved":[{"name":"Acute bacterial epiglottitis","source":"DrugCentral","snomedId":21060003,"regulator":"FDA","eligibility":null},{"name":"Acute bacterial sinusitis","source":"DrugCentral","snomedId":75498004,"regulator":"FDA","eligibility":null},{"name":"Acute epiglottitis","source":"DrugCentral","snomedId":29608009,"regulator":"FDA","eligibility":null},{"name":"Acute exacerbation of chronic bronchitis","source":"DrugCentral","snomedId":425748003,"regulator":"FDA","eligibility":null},{"name":"Acute gonococcal cervicitis","source":"DrugCentral","snomedId":20943002,"regulator":"FDA","eligibility":null},{"name":"Acute gonococcal endometritis","source":"DrugCentral","snomedId":65295003,"regulator":"FDA","eligibility":null},{"name":"Acute gonococcal urethritis","source":"DrugCentral","snomedId":29864006,"regulator":"FDA","eligibility":null},{"name":"Acute otitis media","source":"DrugCentral","snomedId":3110003,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":709000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2026 (PMID:41640273)"},{"name":"Bacterial endocarditis","source":"DrugCentral","snomedId":301183007,"regulator":"FDA","eligibility":null},{"name":"Bacterial meningitis","source":"DrugCentral","snomedId":95883001,"regulator":"FDA","eligibility":null},{"name":"Bacterial peritonitis","source":"DrugCentral","snomedId":197171003,"regulator":"FDA"},{"name":"Bacterial pneumonia","source":"DrugCentral","snomedId":53084003,"regulator":"FDA"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA"},{"name":"Bacteroides Gynecological Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Cesarean Section Infection Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Cholangitis","source":"DrugCentral","snomedId":82403002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":648000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (22245904[PMID])"},{"name":"Dysentery","source":"DrugCentral","snomedId":111939009,"regulator":"FDA"},{"name":"E. Coli Gynecological Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"E. Coli Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterococcus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Escherichia coli meningitis","source":"DrugCentral","snomedId":192655005,"regulator":"FDA"},{"name":"Female genital tract infection","source":"DrugCentral","snomedId":125585007,"regulator":"FDA"},{"name":"Gastroenteritis due to Salmonella","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Genitourinary Tract Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Gonorrhea","source":"DrugCentral","snomedId":15628003,"regulator":"FDA"},{"name":"Gonorrhea of rectum","source":"DrugCentral","snomedId":42746002,"regulator":"FDA"},{"name":"Haemophilus Influenzae Acute Otitis Media","source":"DrugCentral","snomedId":19021002,"regulator":"FDA"},{"name":"Haemophilus Influenzae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Influenzae Pharyngitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus influenzae pneumonia","source":"DrugCentral","snomedId":70036007,"regulator":"FDA"},{"name":"Infection Prevention for GI Surgery","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Infection due to Enterobacteriaceae","source":"DrugCentral","snomedId":128945009,"regulator":"FDA"},{"name":"Infection due to Escherichia coli","source":"DrugCentral","snomedId":71057007,"regulator":"FDA"},{"name":"Infection due to Staphylococcus aureus","source":"DrugCentral","snomedId":406602003,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disease of abdomen","source":"DrugCentral","snomedId":128070006,"regulator":"FDA"},{"name":"Infective otitis media","source":"DrugCentral","snomedId":312218008,"regulator":"FDA"},{"name":"Inflammatory Disease of Female Pelvic Organs","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Intra-Abdominal E. Coli Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Klebsiella Pneumoniae Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Meningococcal meningitis","source":"DrugCentral","snomedId":192644005,"regulator":"FDA"},{"name":"Neonatal Group B Streptococcal Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Paratyphoid fever","source":"DrugCentral","snomedId":85904008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2000000000,"prevalenceMethod":"curated","prevalenceSource":"Common symptom, not a disease"},{"name":"Pharyngitis","source":"DrugCentral","snomedId":405737000,"regulator":"FDA"},{"name":"Pneumococcal Acute Otitis Media","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pneumococcal meningitis","source":"DrugCentral","snomedId":51169003,"regulator":"FDA"},{"name":"Pneumococcal pharyngitis","source":"DrugCentral","snomedId":76651006,"regulator":"FDA"},{"name":"Pneumococcal pneumonia","source":"DrugCentral","snomedId":233607000,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Proteus septicemia","source":"DrugCentral","snomedId":300986008,"regulator":"FDA"},{"name":"Proteus urinary tract infection","source":"DrugCentral","snomedId":301012009,"regulator":"FDA"},{"name":"Rhinoscleroma","source":"DrugCentral","snomedId":72409005,"regulator":"FDA"},{"name":"Salmonella septicemia","source":"DrugCentral","snomedId":49786009,"regulator":"FDA"},{"name":"Sepsis due to Staphylococcus aureus","source":"DrugCentral","snomedId":448417001,"regulator":"FDA"},{"name":"Septicemia due to Escherichia coli","source":"DrugCentral","snomedId":9323009,"regulator":"FDA"},{"name":"Septicemia due to enterococcus","source":"DrugCentral","snomedId":310669007,"regulator":"FDA"},{"name":"Shigellosis","source":"DrugCentral","snomedId":36188001,"regulator":"FDA"},{"name":"Sinusitis","source":"DrugCentral","snomedId":36971009,"regulator":"FDA"},{"name":"Skin and Skin Structure Acinetobacter Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Bacteroides Fragilis Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Proteus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":251400000,"prevalenceMethod":"curated","prevalenceSource":"Pathogens, 2024 (PMID:39452777)"},{"name":"Staphylococcal endocarditis","source":"DrugCentral","snomedId":73028002,"regulator":"FDA"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"},{"name":"Staphylococcus Acute Otitis Media","source":"DrugCentral","snomedId":703469002,"regulator":"FDA"},{"name":"Staphylococcus Epidermidis Skin and Skin Structure Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcal Endocarditis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcal septicemia","source":"DrugCentral","snomedId":29577008,"regulator":"FDA"},{"name":"Streptococcal tonsillitis","source":"DrugCentral","snomedId":41582007,"regulator":"FDA"},{"name":"Streptococcus Pneumoniae Chronic Bronchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Urinary tract infectious disease","source":"DrugCentral","snomedId":68566005,"regulator":"FDA"},{"name":"Vaginal Hysterectomy Infection Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Anthrax","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":45,"evidenceLevel":"moderate"},{"name":"Cat bite - wound","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":20,"evidenceLevel":"moderate"},{"name":"Cutaneous listeriosis","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":7,"evidenceLevel":"emerging"},{"name":"Diabetic Foot Infection","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":127,"evidenceLevel":"strong"},{"name":"Diverticulitis of gastrointestinal tract","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Dog bite - wound","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Enterocolitis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Gastrointestinal anthrax","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Granulomatosis Infantiseptica","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"H. Influenzae Meningitis","source":"DrugCentral","drugName":"AMPICILLIN","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Haemophilus Parainfluenzae Acute Otitis Media","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Haemophilus Parainfluenzae Chronic Bronchitis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Haemophilus Parainfluenzae Pneumonia","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Human bite - wound","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Infection by Campylobacter fetus","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Infection of bone","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Inhalational anthrax","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Listeria Monocytogenes Septicemia","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Listeria Osteomyelitis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Listeria Septic Arthritis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Listeria meningitis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Listerial endocarditis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Listeriosis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Necrotizing enterocolitis in fetus OR newborn","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Neonatal meningitis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Neonatal pneumonia","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Pharyngitis due to Haemophilus Parainfluenzae","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Prevention of Bacterial Endocarditis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Prevention of Neonatal Group B Streptococcal Infection","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Pseudotuberculosis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Sepsis of the newborn","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Streptococcal meningitis","source":"DrugCentral","drugName":"AMPICILLIN"},{"name":"Typhoid fever","source":"DrugCentral","drugName":"AMPICILLIN"}],"pipeline":[]},"currentOwner":"Apothecon","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"carbenicillin","brandName":"carbenicillin","genericName":"carbenicillin","approvalYear":"","relationship":"same-class"},{"drugId":"amoxicillin","brandName":"amoxicillin","genericName":"amoxicillin","approvalYear":"1974","relationship":"same-class"},{"drugId":"carindacillin","brandName":"carindacillin","genericName":"carindacillin","approvalYear":"1972","relationship":"same-class"},{"drugId":"bacampicillin","brandName":"bacampicillin","genericName":"bacampicillin","approvalYear":"1980","relationship":"same-class"},{"drugId":"azlocillin","brandName":"azlocillin","genericName":"azlocillin","approvalYear":"1982","relationship":"same-class"},{"drugId":"mezlocillin","brandName":"mezlocillin","genericName":"mezlocillin","approvalYear":"1981","relationship":"same-class"},{"drugId":"mecillinam","brandName":"mecillinam","genericName":"mecillinam","approvalYear":"","relationship":"same-class"},{"drugId":"piperacillin","brandName":"piperacillin","genericName":"piperacillin","approvalYear":"1981","relationship":"same-class"},{"drugId":"ticarcillin","brandName":"ticarcillin","genericName":"ticarcillin","approvalYear":"1976","relationship":"same-class"},{"drugId":"hetacillin","brandName":"hetacillin","genericName":"hetacillin","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":["Acute Uncomplicated Diverticulitis"],"enrollment":100,"completionDate":"2028-10-01"},{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":["Helicobacter Pylori Eradication","Adverse Reaction"],"enrollment":640,"completionDate":"2026-03-10"},{"nctId":"NCT05761080","phase":"PHASE4","title":"Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-04-22","conditions":["Laparoscopic Appendectomy","Complicated Appendicitis","Periappendicular Abscess"],"enrollment":772,"completionDate":"2027-12"},{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":["Febrile Neutropenia"],"enrollment":55,"completionDate":"2025-12-17"},{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":["Infection","Sepsis","NICU","PICU","Beta Lactams"],"enrollment":110,"completionDate":"2028-04"},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":["Mycobacterium Abscessus Pulmonary Disease","Mycobacterium Abscessus Infection","Non-Tuberculous Mycobacterial (NTM) Infections","Non-Tuberculous Mycobacteria Pulmonary Disease"],"enrollment":300,"completionDate":"2031-07"},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":["Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction"],"enrollment":300,"completionDate":"2028-12-31"},{"nctId":"NCT07481539","phase":"PHASE2","title":"Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment","status":"RECRUITING","sponsor":"Azienda Sanitaria Universitaria Friuli Centrale","startDate":"2026-03-24","conditions":["Bacteria Infection","Piperacillin, Tazobactam Drug Combination"],"enrollment":240,"completionDate":"2027-04-30"},{"nctId":"NCT07483736","phase":"PHASE3","title":"Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-03","conditions":["C15.378"],"enrollment":1526,"completionDate":"2028-09"},{"nctId":"NCT06154174","phase":"NA","title":"Choline to Improve Malnutrition and Enhance Cognition","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-12-05","conditions":["Severe Acute Malnutrition","Cognitive Impairment","Wasting","Kwashiorkor"],"enrollment":1500,"completionDate":"2026-11"},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":["Sepsis"],"enrollment":1900,"completionDate":"2033-05"},{"nctId":"NCT05834036","phase":"PHASE4","title":"Effect of Antibiotics on Enteric Neurons and Glia","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2023-06-23","conditions":["Antibiotic Enterocolitis"],"enrollment":10,"completionDate":"2023-11-09"},{"nctId":"NCT00713947","phase":"PHASE4","title":"Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-04","conditions":["Positive Helicobacter Pylori Serology","Coronary Thrombosis","Supra-aortic Artery Thrombosis"],"enrollment":0,"completionDate":"2010-03"},{"nctId":"NCT07457385","phase":"PHASE4","title":"Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-11-01","conditions":["Syphilis, Congenital"],"enrollment":374,"completionDate":"2031-08-31"},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":["Small Intestine Bacterial Overgrowth"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT03078010","phase":"PHASE2","title":"Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-10","conditions":["Intestinal Microbiome","Febrile Neutropenia"],"enrollment":347,"completionDate":"2027-02"},{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":["Sinus Infection","Acute Sinusitis"],"enrollment":3720,"completionDate":"2028-12"},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":["Community Acquired Pneumonia in Children"],"enrollment":236,"completionDate":"2028-05"},{"nctId":"NCT07442357","phase":"NA","title":"The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial","status":"NOT_YET_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-06-01","conditions":["Aortic Valve Stenosis"],"enrollment":1986,"completionDate":"2029-06-01"},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":["Neovascular Age-Related Macular Degeneration (nAMD)"],"enrollment":146,"completionDate":"2027-02"},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Endocarditis Infective"],"enrollment":360,"completionDate":"2027-12-30"},{"nctId":"NCT06340724","phase":"PHASE3","title":"Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-02-15","conditions":["Helicobacter Pylori Infection"],"enrollment":104,"completionDate":"2025-01-15"},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":["Helicobacter Pylori Infection"],"enrollment":337,"completionDate":"2024-12-03"},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":["Acute Kidney Injury"],"enrollment":750,"completionDate":"2029-07"},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":["HELICOBACTER PYLORI INFECTIONS","Helicobacter Infection","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients"],"enrollment":66,"completionDate":"2026-12-20"},{"nctId":"NCT02701595","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":["Infective Endocarditis"],"enrollment":324,"completionDate":"2023-06-24"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT07399717","phase":"NA","title":"Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Anabio R&D","startDate":"2026-01-26","conditions":["Pneumonia","Pneumonia in Children"],"enrollment":330,"completionDate":"2027-12-30"},{"nctId":"NCT06123169","phase":"PHASE3","title":"Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-04","conditions":["Pancreaticoduodenectomy","Antibiotherapy"],"enrollment":326,"completionDate":"2028-07"},{"nctId":"NCT05100654","phase":"EARLY_PHASE1","title":"Collaborative Urological Prosthetics Investigation Directive Research Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2022-04-22","conditions":["Erectile Dysfunction","Penile Prosthesis Infection"],"enrollment":800,"completionDate":"2028-01-01"},{"nctId":"NCT06336213","phase":"NA","title":"Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients","status":"RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2024-01-23","conditions":["Aortic Aneurysm and Dissection","Cardiac Valve Disease","Thoracic Aortic Aneurysm","Thoracic Aortic Dissection"],"enrollment":50,"completionDate":"2027-02-15"},{"nctId":"NCT04986254","phase":"","title":"PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-17","conditions":["Pneumonia"],"enrollment":179,"completionDate":"2024-01-31"},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":["Preterm Premature Rupture of Membrane","Pregnancy, High Risk","Preterm Birth"],"enrollment":56,"completionDate":"2026-12"},{"nctId":"NCT06229288","phase":"PHASE3","title":"Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-25","conditions":["Community-acquired Pneumonia"],"enrollment":326,"completionDate":"2027-05-25"},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":["Chemotherapy Effect"],"enrollment":198,"completionDate":"2027-07-31"},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":["Helicobacter Pylori Infection"],"enrollment":552,"completionDate":"2027-12-31"},{"nctId":"NCT06440304","phase":"PHASE4","title":"Therapeutic Options for CRAB","status":"RECRUITING","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2025-01-30","conditions":["Infections, Bacterial","Sepsis Bacterial"],"enrollment":108,"completionDate":"2027-02"},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":["Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Cefazolin","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin"],"enrollment":300,"completionDate":"2026-07-01"},{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":["Helicobacter Pylori Infection"],"enrollment":370,"completionDate":"2025-10-31"},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":["Helicobacter Pylori Eradication"],"enrollment":390,"completionDate":"2026-12-31"},{"nctId":"NCT02783859","phase":"PHASE4","title":"Hospitalised Pneumonia With Extended Treatment (HOPE) Study","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2016-06","conditions":["Pneumonia"],"enrollment":314,"completionDate":"2022-12"},{"nctId":"NCT04549311","phase":"PHASE3","title":"Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-11-18","conditions":["Perianal Abscess","Perianal Fistula"],"enrollment":15,"completionDate":"2023-01-22"},{"nctId":"NCT07015736","phase":"PHASE4","title":"Effects of Saccharomyces Boulardii CNCM I-745 on Antibiotic-Associated Perturbation in Children Treated for Acute Respiratory Infections (RESTORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eskisehir Osmangazi University","startDate":"2025-08-01","conditions":["Antibiotic Associated Diarrhea","Acute Otitis Media","ACUTE SINUSITIS"],"enrollment":100,"completionDate":"2026-07-31"},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":["Hospital Acquired Bacterial Pneumonia (HABP)","Ventilator Associated Bacterial Pneumonia (VABP)","Colistin Resistanrt ABC","Acinetobacter Baumannii-calcoaceticus Complex"],"enrollment":248,"completionDate":"2028-03-30"},{"nctId":"NCT03481881","phase":"","title":"Pharmacokinetics of Drugs Administered to Children","status":"RECRUITING","sponsor":"Duke University","startDate":"2013-08-14","conditions":["Pediatric ALL"],"enrollment":200,"completionDate":"2033-08-14"},{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":["E Coli Infection","ESBL Producing E.Coli"],"enrollment":84,"completionDate":"2028-08"},{"nctId":"NCT07294846","phase":"PHASE1","title":"Drug Interaction Study on Linaprazan Glurate Capsules","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2025-09-08","conditions":["Healthy Volunteers","Patients"],"enrollment":56,"completionDate":"2025-12-15"},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":["Aspiration","Aspiration Pneumonia"],"enrollment":5,"completionDate":"2024-04-12"},{"nctId":"NCT07296302","phase":"NA","title":"Antibiotic Prophylaxis Versus Placebo in Alveolar Bone Grafting: A Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Agnaldo Rocha de Souza Junior","startDate":"2026-02","conditions":["Alveolar Ridge Augmentation","Bone Grafting","Antibiotic Prophylaxis"],"enrollment":150,"completionDate":"2027-08"},{"nctId":"NCT07304882","phase":"PHASE3","title":"A Comparison of Recovery After Impacted Wisdom Tooth Removal","status":"COMPLETED","sponsor":"University of Science and Technology, Yemen","startDate":"2023-11-30","conditions":["Impacted Mandibular Third Molar Extraction","Post Operative Complications"],"enrollment":24,"completionDate":"2025-01-04"},{"nctId":"NCT07275827","phase":"PHASE3","title":"Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":88,"completionDate":"2026-10"},{"nctId":"NCT02281929","phase":"PHASE3","title":"Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2015-06-13","conditions":["Alcoholic Hepatitis","Alcoholic Liver Disease"],"enrollment":297,"completionDate":"2019-11-19"},{"nctId":"NCT07183462","phase":"PHASE4","title":"Azithromycin and Ampicillin for Late PPROM","status":"RECRUITING","sponsor":"Sheba Medical Center","startDate":"2025-09-10","conditions":["Pregnancy Complications, Infectious","Premature Birth","Neonatal Diseases and Abnormalities","Antibiotic Prophylaxis","Latency Period","Prematurity"],"enrollment":311,"completionDate":"2029-07-31"},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":["Febrile Urinary Tract Infection"],"enrollment":560,"completionDate":"2029-03"},{"nctId":"NCT06869850","phase":"NA","title":"Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-09-22","conditions":["Severe Acute Malnutrition","Cognitive Impairment","Kwashiorkor","Severe Wasting"],"enrollment":1600,"completionDate":"2027-12-01"},{"nctId":"NCT05309928","phase":"PHASE1","title":"Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2023-08-29","conditions":["Pregnancy Related"],"enrollment":13,"completionDate":"2025-06-30"},{"nctId":"NCT05926804","phase":"NA","title":"A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","status":"RECRUITING","sponsor":"Miguel O'Ryan Gallardo","startDate":"2022-08-02","conditions":["Helicobacter Pylori Infection"],"enrollment":500,"completionDate":"2027-08"},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":["Community-acquired Pneumonia"],"enrollment":330,"completionDate":"2026-07-30"},{"nctId":"NCT07275580","phase":"PHASE4","title":"Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-10","conditions":["Autoimmune Rheumatic Diseases","Tooth Extraction","Infection Prevention","Antibiotic Prophylaxis"],"enrollment":352,"completionDate":"2029-02-10"},{"nctId":"NCT04350502","phase":"NA","title":"Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2019-07-18","conditions":["Pleural Infection","Empyema","Community-acquired Pneumonia","Pharmacokinetic","Amoxicillin"],"enrollment":11,"completionDate":"2025-12-01"},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":["Urinary Tract Infections"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":["Helicobacter Pylori Infection","Helicobacter Pylori Infected Patients","Helicobacter Pylori Infected Subjects"],"enrollment":461,"completionDate":"2025-04-24"},{"nctId":"NCT06734260","phase":"PHASE3","title":"Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Eighth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-09-10","conditions":["Helicobacter Pylori Eradication Rate"],"enrollment":477,"completionDate":"2026-01-10"},{"nctId":"NCT07260006","phase":"NA","title":"Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease","status":"RECRUITING","sponsor":"Can Tho University of Medicine and Pharmacy","startDate":"2024-10-01","conditions":["Helicobacter Pylori Infection","Peptic Ulcer"],"enrollment":80,"completionDate":"2026-05-30"},{"nctId":"NCT06823154","phase":"PHASE1","title":"The Implementation and Impact of an Allergy De-Labeling Program in the Emergency Department","status":"ENROLLING_BY_INVITATION","sponsor":"The Hospital for Sick Children","startDate":"2023-11-27","conditions":["Allergy Amoxicillin","Beta-lactam Allergy Labels"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT06126731","phase":"PHASE1,PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"enrollment":39,"completionDate":"2027-06-30"},{"nctId":"NCT07242456","phase":"PHASE2,PHASE3","title":"Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication","status":"RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-02-17","conditions":["Helicobacter Pylori Infection"],"enrollment":240,"completionDate":"2026-01-31"},{"nctId":"NCT07242443","phase":"PHASE4","title":"Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","status":"NOT_YET_RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-11-20","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":["Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit"],"enrollment":398,"completionDate":"2019-02-09"},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":["Administration of Antibiotics in Intensive Care Units"],"enrollment":98,"completionDate":"2012-04-01"},{"nctId":"NCT07233733","phase":"NA","title":"A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects","status":"COMPLETED","sponsor":"Phạm Đình Thiên Khải","startDate":"2024-06-01","conditions":["Periodontal Diseases","Regeneration"],"enrollment":17,"completionDate":"2025-08-01"},{"nctId":"NCT03269994","phase":"PHASE3","title":"Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-21","conditions":["Pancreatic Cancer","Pancreas Cancer","Pancreatic Diseases"],"enrollment":967,"completionDate":"2025-01-28"},{"nctId":"NCT05846399","phase":"PHASE4","title":"CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2023-09-07","conditions":["Cat Bite","Hand Injuries","Arm Injury","Infection, Bacterial","Anti-bacterial Agents"],"enrollment":72,"completionDate":"2027-08-01"},{"nctId":"NCT06010719","phase":"PHASE4","title":"Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-23","conditions":["Malnutrition, Child","Severe Acute Malnutrition"],"enrollment":3000,"completionDate":"2028-12-29"},{"nctId":"NCT07202091","phase":"PHASE2,PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":["Myeloma","Leukemia","Non Hodgkin's Lymphoma"],"enrollment":900,"completionDate":"2027-03-31"},{"nctId":"NCT07202052","phase":"PHASE2,PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":["Myeloma","Non-Hodgkin's Lymphoma","Leukemia"],"enrollment":900,"completionDate":"2027-03-31"},{"nctId":"NCT07096310","phase":"PHASE1,PHASE2","title":"Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":["Sepsis"],"enrollment":400,"completionDate":"2026-03-01"},{"nctId":"NCT06368102","phase":"PHASE4","title":"Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery","status":"COMPLETED","sponsor":"Uji Takeda Hospital","startDate":"2024-05-02","conditions":["Surgical Site Infection"],"enrollment":70,"completionDate":"2025-09-01"},{"nctId":"NCT03997266","phase":"PHASE4","title":"NICU Antibiotics and Outcomes Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Morowitz","startDate":"2020-08-05","conditions":["Microbial Colonization","Extreme Prematurity","Early-Onset Neonatal Sepsis","Late-Onset Neonatal Sepsis","Necrotizing Enterocolitis of Newborn","Death; Neonatal"],"enrollment":802,"completionDate":"2027-06-01"},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":["Helicobacter Pylori Infection"],"enrollment":450,"completionDate":"2025-12"},{"nctId":"NCT03915366","phase":"PHASE2,PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":["Pneumonia","HIV/AIDS","Tuberculosis","Cytomegalovirus Infections"],"enrollment":563,"completionDate":"2025-01-31"},{"nctId":"NCT01015417","phase":"PHASE3","title":"Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2010-05","conditions":["Acute Lithiasic Cholecystitis Grade I or II","Symptoms Lasting for Less Than 5 Days","Required Cholecystectomy","Preoperative Amoxicillin Clavulanic Acid for at Most 5 Days"],"enrollment":414,"completionDate":"2012-11"},{"nctId":"NCT06273891","phase":"PHASE3","title":"Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2024-03-08","conditions":["Premature Rupture of Membrane"],"enrollment":140,"completionDate":"2026-10-01"},{"nctId":"NCT04728516","phase":"PHASE4","title":"The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-04-12","conditions":["Acute Coronary Syndrome","Helicobacter Pylori Infection"],"enrollment":2600,"completionDate":"2026-06-30"},{"nctId":"NCT05874544","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-16","conditions":["Helicobacter Pylori Infection"],"enrollment":360,"completionDate":"2025-01-31"},{"nctId":"NCT02707042","phase":"PHASE1","title":"Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-22","conditions":["Normal Physiology","Healthy"],"enrollment":108,"completionDate":"2025-05-15"},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":["Preterm Premature Rupture of Membranes (PPROM)","Prophylaxis","Perinatal Outcomes"],"enrollment":40,"completionDate":"2025-08-10"},{"nctId":"NCT06451913","phase":"PHASE4","title":"Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))","status":"RECRUITING","sponsor":"Biocodex","startDate":"2025-07-16","conditions":["Erythema Migrans of Lyme Disease"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":["Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection"],"enrollment":94,"completionDate":"2025-02-14"},{"nctId":"NCT05464615","phase":"EARLY_PHASE1","title":"Geisinger Antibiotic Allergy Pilot Program: Assess and Address","status":"RECRUITING","sponsor":"Geisinger Clinic","startDate":"2024-03-04","conditions":["Penicillin Allergy"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT03273296","phase":"PHASE4","title":"Effect of Antibiotics on Gut Microbiome and Plasma Metabolome","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2017-10-15","conditions":["Microbial Colonization"],"enrollment":39,"completionDate":"2017-12-15"},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":["H.Pylori Infection"],"enrollment":700,"completionDate":"2024-03-26"},{"nctId":"NCT07113587","phase":"PHASE2,PHASE3","title":"Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis","status":"COMPLETED","sponsor":"Karl Landsteiner Insitute for Nephrology and Haemato-Oncology","startDate":"2014-04-08","conditions":["Peritoneal Dialysis-associated Peritonitis","Peritoneal Dialysis (PD)","Pharmacokinetics","Intravenous Administration","Intravenous","Meropenem","Intraperitoneal","Ampicillin","Aztreonam","Ciprofloxacin","Minimum Inhibitory Concentration (MIC)"],"enrollment":24,"completionDate":"2017-07-07"},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":["Helicobacter Pylori"],"enrollment":414,"completionDate":"2025-12-30"},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":["Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer"],"enrollment":400,"completionDate":"2025-11-01"},{"nctId":"NCT07115173","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-12-01","conditions":["Helicobacter Infection"],"enrollment":103,"completionDate":"2027-12-31"},{"nctId":"NCT07118384","phase":"NA","title":"Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-05-01","conditions":["Acinetobacter Baumannii Infection"],"enrollment":50,"completionDate":"2026-01"},{"nctId":"NCT06131021","phase":"PHASE3","title":"Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-04-25","conditions":["Periodontitis","Periodontal Diseases","Periodontal Pocket"],"enrollment":150,"completionDate":"2026-05-26"},{"nctId":"NCT07107477","phase":"PHASE3","title":"TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden","status":"RECRUITING","sponsor":"The Central and Eastern European Gynecologic Oncology Group","startDate":"2025-05-01","conditions":["Preterm Premature Rupture of Membranes (PPROM)"],"enrollment":138,"completionDate":"2028-05-01"},{"nctId":"NCT05469984","phase":"NA","title":"Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2022-11-25","conditions":["Preterm Labor With Preterm Delivery","Premature Rupture of Membranes Prolonged"],"enrollment":600,"completionDate":"2025-09-26"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Capsule, Injection","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Ampicillin"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"AMPICILLIN"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Ampicillin"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Ampicillin Sodium and Sulbactam Sodium"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Ampicillin and Sulbactam"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"UNASYN"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"ampicillin and sulbactam"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"ampicillin sodium and sulbactam sodium"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"UNASYN"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"AMPICILLIN"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"AMPICILLIN and SULBACTAM"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Ampicillin"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Ampicillin Sodium"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Ampicillin and Sulbactam"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Ampicillin sodium"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000145927","MMSL":"17720","NDDF":"002692","UNII":"7C782967RD","VUID":"4017545","CHEBI":"CHEBI:28971","VANDF":"4017543","INN_ID":"1339","RXNORM":"203115","UMLSCUI":"C0002680","chemblId":"CHEMBL1200758","ChEMBL_ID":"CHEMBL174","KEGG_DRUG":"D01251","DRUGBANK_ID":"DB00415","PDB_CHEM_ID":" AIC","PUBCHEM_CID":"6249","SNOMEDCT_US":"1268946000","IUPHAR_LIGAND_ID":"10896","SECONDARY_CAS_RN":"69-52-3","MESH_DESCRIPTOR_UI":"D000667"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1965-","companyName":"Wyeth Ayerst","relationship":"Original Developer"},{"period":"present","companyName":"Apothecon","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.4 hours","clearance":"2.8 mL/min/kg","bioavailability":"62%","fractionUnbound":"0.85%","volumeOfDistribution":"0.22 L/kg"},"publicationCount":30372,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J01CA01","allCodes":["J01CA01","J01CA51","J01CR01","S01AA19"]},"biosimilarFilings":[],"originalDeveloper":"Wyeth Ayerst","recentPublications":[{"date":"2026 Mar 27","pmid":"41905715","title":"Assessing Antibiotic Utilization Trends and Outcomes In Patients With Carbapenem-Resistant Acinetobacter Baumannii (CRAB) Infections.","journal":"American journal of infection control"},{"date":"2026 Mar 26","pmid":"41903866","title":"Factors influencing the efficacy of nebulized colistimethate sodium in the treatment of severe lung infection caused by carbapenem-resistant gram-negative bacteria.","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"},{"date":"2026 Mar 26","pmid":"41903649","title":"Bloody diarrhea associated with cytotoxic Aeromonas enteropelogenes harboring act and aerA genes: A case report highlighting diagnostic pitfalls.","journal":"Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy"},{"date":"2026 Feb 9","pmid":"41903513","title":"Predictors, aetiology and outcome of early-onset neonatal bloodstream infection: a case-control study in a tertiary hospital in South Africa.","journal":"Journal of tropical pediatrics"},{"date":"2026 Mar 28","pmid":"41902741","title":"Generation of equine-specific local antibiograms: reproductive tract of mares and fillies in Western Australia.","journal":"Australian veterinary journal"}],"companionDiagnostics":[],"genericManufacturers":18,"_genericFilersChecked":true,"genericManufacturerList":["Apothecon","Aurobindo Pharma","Belcher Pharms","Bristol Myers Squibb","Chartwell Rx","Glaxosmithkline","Ivax Sub Teva Pharms","Lederle","Mylan","Parke Davis","Pfizer","Ph Health","Purepac Pharm","Sandoz","Strides Pharma Intl","Teva","Vitarine","Wyeth Ayerst"],"status":"approved","companyName":"Apothecon","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"1965","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-04-15T00:00:00.000Z","mah":"HQ SPECLT PHARMA","brand_name_local":null,"application_number":"ANDA062772"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-08-05T00:00:00.000Z","mah":"HQ SPECLT PHARMA","brand_name_local":null,"application_number":"ANDA065188"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-04-09T00:00:00.000Z","mah":"ONESOURCE SPECIALTY","brand_name_local":null,"application_number":"ANDA201025"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-05-01T00:00:00.000Z","mah":"HQ SPECLT PHARMA","brand_name_local":null,"application_number":"ANDA065176"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-04-19T00:00:00.000Z","mah":"ONESOURCE SPECIALTY","brand_name_local":null,"application_number":"ANDA201024"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"179.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:00.779187+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}